Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Stomach Neoplasms 1Rectal Neoplasms 1Lung Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 26atezolizumab 14Nivolumab 13Gemcitabine 13Cisplatin 10Docetaxel 8Carboplatin 8avelumab 7Mitomycin 7epacadostat 4cabozantinib 4Ipilimumab 4pemigatinib 3Specimen Handling 3Paclitaxel 3Magnetic Resonance Spectroscopy 3Bevacizumab 3vofatamab 2rucaparib 2lenvatinib 2enfortumab vedotin 2durvalumab 2cabazitaxel 2bempegaldesleukin 2Standard of Care 2Rogaratinib 2Ramucirumab 2Radiation 2Platinum 2Pemetrexed 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Transitional Cell × IT-101 × Clear all
NCT02769962 2025-07-28

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
45 enrolled 30 charts
GenitourinaryThoracic

Carcinoma, Transitional Cell, Lung Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡